2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Arthritis and Rheumatology

Volumn 69, Issue 8, 2017, Pages 1538-1551

  Goodman, Susan M ^a   Springer, Bryan ^b   Guyatt, Gordon ^c   Abdel, Matthew P ^d   Dasa, Vinod ^e   George, Michael ^f   Gewurz Singer, Ora ^g   Giles, Jon T ^h   Johnson, Beverly ⁱ   Lee, Steve ^j   Mandl, Lisa A ^a   Mont, Michael A ^k   Sculco, Peter ^a   Sporer, Scott ^l   Stryker, Louis ^m   Turgunbaev, Marat ⁿ   Brause, Barry ^a   Chen, Antonia F ^o   Gililland, Jeremy ^p   Goodman, Mark ^q   Hurley Rosenblatt, Arlene ^r   Kirou, Kyriakos ^a   Losina, Elena ^s   MacKenzie, Ronald ^a   Michaud, Kaleb ^t,u   Mikuls, Ted ^u   Russell, Linda ^a   Sah, Alexander ^v   Miller, Amy S ⁿ   Singh, Jasvinder A ^w   Yates, Adolph ^q   more..

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b ORTHOCAROLINA HIP AND KNEE CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MAYO CLINIC   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j KAISER PERMANENTE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l Midwest Orthopaedics at Rush   (United States)

^m UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁿ American College of Rheumatology   (Georgia)

^o THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^p UNIVERSITY OF UTAH   (United States)

^q UNIVERSITY OF PITTSBURGH   (United States)

^r ROCKEFELLER UNIVERSITY   (United States)

^s BRIGHAM AND WOMEN S HOSPITAL   (United States)

^t NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^u UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^v Dearborn Sah Institute for Joint Restoration   (United States)

^w UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BELIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DOXYCYCLINE; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ELECTIVE SURGERY; HIP ARTHROPLASTY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SOCIETY; MEDICATION THERAPY MANAGEMENT; ORTHOPEDIC SURGEON; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TOTAL KNEE ARTHROPLASTY; ARTHRITIS, JUVENILE; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HIP REPLACEMENT; KNEE REPLACEMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; ORTHOPEDICS; PROCEDURES; RHEUMATIC DISEASES; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL PRODUCTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; ORTHOPEDICS; PERIOPERATIVE CARE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RHEUMATIC DISEASES; RHEUMATOLOGY; SOCIETIES, MEDICAL; SPONDYLITIS, ANKYLOSING; UNITED STATES;

EID: 85020881455     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40149     Document Type: Article

References (103)

1. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234–54.
2. Ravi B, Croxford R, Reichmann WM, Losina E, Katz JN, Hawker GA. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol 2012;26:637–47.
3. Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman S, Figgie MP, Mandl LA. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991–2005. J Rheumatol 2014;41:867–74.
4. Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman SM, Figgie MP, Mandl LA. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol 2014;66:1432–9.
5. Nikiphorou E, Carpenter L, Morris S, MacGregor AJ, Dixey J, Kiely P, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheumatol 2014;66:1081–9.
6. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007;66:341–4.
7. Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:254–63.
8. Lin JA, Liao CC, Lee YJ, Wu CH, Huang WQ, Chen TL. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis 2014;73:1646–51.
9. Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken) 2015;67:718–24.
10. Roberts JE, Mandl LA, Su EP, Mayman DJ, Figgie MP, Fein AW, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol 2016;43:1498–502.
11. Goodman SM, Ramsden-Stein DN, Huang WT, Zhu R, Figgie MP, Alexiades MM, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol 2014;41:1774–80.
12. Goodman SM, Johnson B, Zhang M, Huang WT, Zhu R, Figgie M, et al. Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis. J Rheumatol 2016;43:46–53.
13. LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee YY, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case–control study. J Rheumatol 2015;42:1123–30.
14. Johnson BK, Goodman SM, Alexiades MM, Figgie MP, Demmer RT, Mandl LA. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 2013;40:617–23.
15. Berbari EF, Osmon DR, Lahr B, Eckel-Passow JE, Tsaras G, Hanssen AD, et al. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol 2012;33:774–81.
16. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713–20.
17. Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford) 2016;55:573–82.
18. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785–91.
19. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294–300.
20. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 2012;Suppl 27:61–5.
21. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR 2011;60:22–3.
22. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953–62.
23. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
24. Fernando MM, Isenberg DA. How to monitor SLE in routine clinical practice. Ann Rheum Dis 2005;64:524–7.
25. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008;Suppl 1:S3–8.
26. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. 2009 ACCF/AHA focused update on perioperative β blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 2009;54:e13–118.
27. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. 2009 ACCF/AHA focused update on perioperative β blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2009;120:e169–276.
28. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141 Suppl 2:e278S–325S.
29. Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012;94:746–7.
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
31. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995–8.
32. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ 2008;336:1049–51.
33. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices 2: clinical practice guidelines. BMJ 2016;353:i2089.
34. Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P, et al. A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. J Clin Epidemiol 2016;72:45–55.
35. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719–25.
36. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726–35.
37. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214–7.
38. Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 2003;9:115–8.
39. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014;6:CD000957.
40. Goodman SM, Friedlander R, Figgie C, Hoang A, Andersen K, Pernis AB, et al. Flares occur frequently in RA patients undergoing arthroplasty [abstract]. Arthritis Rheumatol 2015;67 Suppl:S2664.
41. Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015;17:362.
42. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258–65.
43. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-α inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015;4:CD005468.
44. Ito H, Kojima M, Nishida K, Matsushita I, Kojima T, Nakayama T, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis. Mod Rheumatol 2015;25:672–8.
45. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2015;1:CD007356.
46. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2014;9:CD007649.
47. Song, GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med 2014;29:656–63.
48. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2924–37.
49. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 2014;127:1208–32.
50. Borba HH, Wiens A, de Souza TT, Correr C, Pontarolo R. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs 2014;28:211–28.
51. He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2013;14:298.
52. Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2013;5:CD004525.
53. Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 2013;33:2199–213.
54. Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol 2013;23:497–506.
55. Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013;72:583–9.
56. Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B 2012;13:731–44.
57. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035–50.
58. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552–62.
59. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011;31:1493–9.
60. Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis 2010;13:12–26.
61. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339–53.
62. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010;25:1–17.
63. An MM, Zou Z, Shen H, Zhang JD, Cao YB, Jiang YY. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66:49–59.
64. Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 2009;70:337–44.
65. Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010;69:1756–61.
66. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136–45.
67. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor α drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
68. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883–90.
69. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398–408.
70. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.
71. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379–84.
72. Capogrosso Sansone A, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Safety 2015;38:869–88.
73. Tarp S, Furst DE, Luta G, Boers M, Tarp U, Asmussen KH, et al. Risk of serious adverse effects associated with different biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]. Ann Rheum Dis 2015;74 Suppl 2:176–7.
74. De la Forest M, Brugneaux J, Utard G, Salliot C. Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]. Ann Rheum Dis 2015;74 Suppl 2:702.
75. Hochberg M, Janssen K, Broglio K, Walsem AV, Nadkarni A. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network meta-analysis [abstract]. Ann Rheum Dis 2014;73 Suppl 2:676.
76. Tarp S, Tarp U, Andersen LS, Lorenzen T, Lindegaard HM, Stoltenberg M, et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum 2013;65 Suppl:S997–8.
77. He Y, Wong A, Chan E, Lau W, Man K, Chui C, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Drug Safety 2013;36:852–3.
78. Singh JA, Wells G, Christensen R, Ghogomu E, Macdonald J, Maxwell L, et al. Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis 2013;72:A74.
79. Ahadieh S, Checchio T, Tensfeldt T, French J, Geier J, Riese R, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. J Pharmacokinetics Pharmacodynamics 2013;40:S93–4.
80. Lin T, Shamliyan T, Choi H, Rho YH, Kuntz K. The safety of anti-TNF biologic agents in rheumatoid arthritis: a meta-analysis of 35 RCTs [abstract]. Arthritis Rheum 2012;64 Suppl:S1854.
81. Venson R, Wiens A, Correr CJ, Pontarolo R. Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazil J Pharm Sci 2012;48:781–91.
82. Cormier H, Barnetche T, Schaeverbeke T. The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a meta-analysis [abstract]. Arthritis Rheum 2011;63 Suppl:S878.
83. Dommasch E, Troxel A, Shin D, Gelfand J, Abuabara K. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol 2011;64:AB8.
84. Rieder S, Thompson A, Pope J. Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol 2010;37:1343.
85. Powers J, Martin R. Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials. J Am Acad Dermatol 2010;62:AB4.
86. Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med 2010;2:749–60.
87. Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res 2007;68:379–99.
88. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34 Suppl 1:12–8.
89. Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 2015;23:71–7.
90. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003;25:1700–21.
91. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–28.
92. Tarp S, Furst DE, Maarten B, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford) 2017;56:417–25.
93. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767–76.
94. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010;29:707–16.
95. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
96. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300–9.
97. Ahadieh S, Checchio T, Tensfeldt T, French J, Krishnaswami S, Riese R, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum 2012;Suppl 63:1697.
98. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311–6.
99. Palmisano AC, Kuhn AW, Urquhart AG, Pour AE. Post-operative medical and surgical complications after primary total joint arthroplasty in solid organ transplant recipients: a case series. Int Orthop 2017;41:13–19.
100. Klement MR, Penrose CT, Bala A, Wellman SS, Bolognesi MP, Seyler TM. How do previous solid organ transplant recipients fare after primary total knee arthroplasty? J Arthroplasty 2016;31:609–15.
101. Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008;143:1222–6.
102. Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1–30.
103. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J 2013;7:119–24.